Search

everythinglearnresearchcommunity

for

Search:↓

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

Stemoxydine is more expensive than minoxidil and finasteride, costing $50-$150 per month. The discussion questions why the cost is higher despite efficacy.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

The conversation discusses using finasteride, dutasteride, minoxidil, cialis, and metformin to protect hair and health. Some users caution against self-prescribing these drugs due to potential risks and complications.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.

A user shared their frustration about their cousin's refusal to take their advice on using finasteride for aggressive hair loss, despite the cousin's desperation and current use of minoxidil and consideration of PRP injections. The user, who has done extensive research, suggested the cousin needs a 5ar inhibitor, but the cousin dismisses the advice because the user isn't a doctor.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Prolactin's role in immune system's antitumor activity raises safety concerns for HMI-115.

The user has maintained their hairline with finasteride for 5 years and saw no results from minoxidil. They are inquiring if tretinoin alone can cause hair regrowth.

The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topical androgen receptor antagonist like RU58841.

The potential accuracy and trustworthiness of websites selling Pyrilutamide, a drug related to hair loss treatments such as Minoxidil, Finasteride, and RU58841; and whether Pyrilutamide is four times stronger than RU58841.

Ordering Pyrilutamide from Minoxidilmax to use as an experimental topical treatment for hair loss, with discussion of the carrier used in trials and encouragement from other users.

Actifollic selling Pyrilutamide as a treatment for hair loss, with people debating its efficacy compared to Minoxidil and Finasteride in combination with RU58841.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

The conversation is about using valproic acid, an anti-seizure medication, as a topical treatment to promote hair growth. The original poster is seeking personal experiences from those who have tried this method.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

Switching from topical to oral minoxidil due to scalp irritation and unsatisfactory results, while also seeking cheaper options in the U.S. Oral minoxidil is generally favored for its effectiveness and fewer application downsides, with CostPlusDrugs and GoodRx offering affordable prices.

Dutasteride is less commonly prescribed for hair loss because it is not FDA-approved for this purpose, unlike finasteride, which is more accessible and preferred due to fewer side effects. Dutasteride may be more effective in reducing DHT but has a longer half-life and potentially more significant side effects.

Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.

The post and conversation discuss KX-826 (pyrilutamide) for hair loss treatment, with positive remarks about its advertising and authenticity in China. The user changed their perspective after further research and seeing genuine advertising.

Finasteride can take years to show results, not months. Dutasteride may work faster but is less commonly prescribed.

The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A user shared a 9-month update on hair loss treatment, reporting positive results from taking 1 mg of finasteride and 1.25 mg of minoxidil daily. The discussion includes varied experiences with these treatments, questions about side effects, and comments on the unpredictability of treatment effectiveness.

The user successfully treated their hair loss using 1ml of minoxidil twice daily and dermarolling with a 1.5mm dermaroller once a week. They experienced noticeable results only after combining minoxidil with dermarolling, and they have not used finasteride.

A user shared a 6-month hair loss treatment routine including Mexican finasteride (1.25mg every other day), daily minoxidil, bi-weekly dermarolling, and ketoconazole shampoo twice a week, noting significant crown growth and some frontal hairline improvement with initial side effects that have since subsided. They are seeking advice to improve results, particularly at the frontal hairline, without resorting to a hair transplant.

The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.